MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Aktien・Krystal Biotech Inc

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

260.53 0.67

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

249.98

Max

260.64

Schlüsselkennzahlen
By Trading Economics
Einkommen	-28M 51M
Verkäufe	9.3M 107M
KGV Branchendurchschnitt	36.102 56.063
Gewinnspanne	47.99
Angestellte	295
EBITDA	-10M 40M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+25.53% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-798M 7.2B
Vorheriger Eröffnungskurs	259.86
Vorheriger Schlusskurs	260.53

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

133.221 / 169.73 Unterstützung & Widerstand

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Apr. 2026, 17:11 UTC

Wichtige Markttreiber

Wichtige Nachrichtenereignisse

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2. Apr. 2026, 17:10 UTC

Wichtige Nachrichtenereignisse

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3. Apr. 2026, 00:00 UTC

Wichtige Nachrichtenereignisse

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2. Apr. 2026, 23:47 UTC

Market Talk

Wichtige Nachrichtenereignisse

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2. Apr. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2. Apr. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2. Apr. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2. Apr. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2. Apr. 2026, 21:01 UTC

Wichtige Nachrichtenereignisse

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2. Apr. 2026, 20:59 UTC

Akquisitionen, Fusionen, Übernahmen

Starbucks and Boyu Capital Finalize China JV

2. Apr. 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Apr. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2. Apr. 2026, 20:41 UTC

Ergebnisse

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. Apr. 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2. Apr. 2026, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. Apr. 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2. Apr. 2026, 20:01 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. Apr. 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2. Apr. 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2. Apr. 2026, 19:29 UTC

Akquisitionen, Fusionen, Übernahmen

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2. Apr. 2026, 19:24 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2. Apr. 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2. Apr. 2026, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2. Apr. 2026, 19:00 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific: Agreement Reached With American Train Dispatchers Association

2. Apr. 2026, 18:24 UTC

Akquisitionen, Fusionen, Übernahmen

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2. Apr. 2026, 17:44 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2. Apr. 2026, 17:32 UTC

Wichtige Nachrichtenereignisse

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2. Apr. 2026, 17:26 UTC

Ergebnisse

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2. Apr. 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2. Apr. 2026, 17:09 UTC

Market Talk

Wichtige Nachrichtenereignisse

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

25.53% Vorteil

12-Monats-Prognose

Durchschnitt 325 USD 25.53%

Hoch 371 USD

Tief 284 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Krystal Biotech Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

133.221 / 169.73Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.